Cornerstone Advisory’s AYTU BioPharma AYTU Stock Holding History

Cornerstone Advisory’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-55	Closed	-$16K	–	189
2020 Q2	$16K	Buy	+55	New	+$16.7K	﹤0.01%	164

Other funds holding AYTU

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cornerstone Advisory's AYTU Position: Q3 2020 in Review

Cornerstone Advisory sold out of AYTU BioPharma (AYTU) in Q3 2020, closing a stake of 55 shares — an estimated $16K sold.

Cornerstone Advisory first reported a position in AYTU in Q2 2020 and held it in 1 quarter. The position peaked at $16K in Q2 2020. 57 funds tracked by Wall St. Rank hold AYTU as of Q3 2020.

Cornerstone Advisory reported no remaining AYTU BioPharma position as of Q3 2020 after selling out during the quarter.
Cornerstone Advisory sold 55 AYTU BioPharma shares in Q3 2020, an estimated $16K.
Cornerstone Advisory first reported a position in AYTU BioPharma in Q2 2020 and held it in 1 quarter.
Cornerstone Advisory's AYTU BioPharma position peaked at $16K in Q2 2020.
57 funds tracked by Wall St. Rank held AYTU BioPharma as of Q3 2020.

Based on Cornerstone Advisory's 13F filing for Q3 2020, filed 12 Nov 2020.